Supplier · Large organisation

Celltrion Healthcare United Kingdom Limited

Celltrion Healthcare United Kingdom Limited has won 23 UK public contracts worth £1.51bn since 11 Jan 2021.

Company 11685363Companies House record Based in South EastFirst contract 11 Jan 2021Latest contract 18 Dec 2025

Contracts: 23
Published value: £1.51bnwhere stated
Without competition: 0%0 contracts
Won by SMEs: 22%of 23 with size known

Contracts won per month, last 24 months 13 contracts · busiest month December 2025

Dec 24
Mar 25
Jun 25
Sep 25
4Dec 25
Mar 26
Jun 26
Sep 26

Biggest customers

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") 10 contracts · £134m
NHS England 7 contracts · £986m
The NHS Commissioning Board (operating under the name of NHS England) 3 contracts · £3
Regional Business Services Organisation Procurement and Logistics Service 2 contracts · £384m
eTenderwales 1 contract · £6.48m

What they supply

Medical equipment & pharmaceuticals 21 contracts · £1.13bn
Health & social care 2 contracts · £384m

Competitors in medical equipment & pharmaceuticals

Sector overview

Medtronic Limited 156 contracts · £6.73bn
NHS Supply Chain Coordination Limited (NHSSC - SCCL) 117 contracts · £20.2m
B. Braun Medical Limited 107 contracts · £5.7bn
Johnson & Johnson Medical Limited 94 contracts · £3.38bn
Stryker UK Limited 70 contracts · £2.09bn
Boston Scientific Limited 67 contracts · £3.36bn

These are the suppliers with the most medical equipment & pharmaceuticals contracts in the last two years, which is where Celltrion Healthcare United Kingdom Limited wins most of its work. They are not necessarily bidding for the same contracts. See the whole sector.

All contracts won by Celltrion Healthcare United Kingdom Limited

Contracts won by Celltrion Healthcare United Kingdom Limited
Date	Contract	Buyer	Value
18 Dec 2025	NP49425 Generic and Biosimilar Transition Medicines: Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£26.5m
18 Dec 2025	NP49425 Generic and Biosimilar Transition Medicines: Cytokine Modulators (Omalizumab)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£9.25m
18 Dec 2025	NP49425 Generic and Biosimilar Transition Medicines: Denosumab (Osteoporosis) and Ferric Carboxymaltose	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£2.25m
18 Dec 2025	NP49425 Generic and Biosimilar Transition Medicines: Cancer Medicines (Group 2)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£18.2m
30 Oct 2025	Branded and Biosimilar Ophthalmology: Aflibercept Biosimilar	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£8.69m
1 Jul 2025	NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025	NHS England	£1
1 Jul 2025	NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025	NHS England	£986m
12 Jun 2025	Medicinal Products and Pharma Funded Homecare [5749446]: Medicinal Products - Direct to Trust	Regional Business Services Organisation Procurement and Logistics Service	£210m
12 Jun 2025	Medicinal Products and Pharma Funded Homecare [5749446]: Medicinal Products - with Pharma Funded Homecare Services	Regional Business Services Organisation Procurement and Logistics Service	£174m
23 Apr 2025	Biologic and Biosimilar Medicines	eTenderwales	£6.48m
29 Jan 2025	NP47924 Cytokine Modulators: Infliximab IV	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£44.3m
29 Jan 2025	NP47924 Cytokine Modulators: Infliximab SC	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£4.2m
13 Jan 2025	NP39724 Generic and Biosimilar Cancer Medicines: Range Generic & Biosimilar Cancer Medicines (unranked)	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£1.71m
22 Jul 2024	NHS Branded Medicines Tranche Framework for London and South of England: CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2	NHS England	£1
22 Jul 2024	NHS Branded Medicines Tranche Framework for London and South of England: CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1	NHS England	£1
22 Jul 2024	NHS Branded Medicines Tranche Framework for London and South of England: CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3	NHS England	£1
14 Jul 2023	NHS London Branded Medicines - Tranche B - September 2023: CM/PHR/22/5677/01 - NHS London Branded Medicines - Tranche B Lot 1	NHS England	£1
14 Jul 2023	NHS London Branded Medicines - Tranche B - September 2023: CM/PHR/22/5677/02 - NHS London Branded Medicines - Tranche B Lot 2	NHS England	£1
10 Feb 2021	NHS Framework, North of England, Branded Medicines - Tranche A and Annual Tranche: Lot 2: North of England (NOFE) Annual Tranche	The NHS Commissioning Board (operating under the name of NHS England)	£1
25 Jan 2021	NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.: Lot 2: Midlands and East Cytokine Modulators and other monoclonal antibodies	The NHS Commissioning Board (operating under the name of NHS England)	£1
25 Jan 2021	NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.	The NHS Commissioning Board (operating under the name of NHS England)	£1
11 Jan 2021	Cytokine Modulators: Infliximab IV	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£18.2m
11 Jan 2021	Cytokine Modulators: Infliximab Subcutaneous	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£308k

Contracts are matched to this supplier by company name as published in each notice. If a company appears under slightly different names, some of its contracts may be listed separately. How matching works.